1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Aspira Pathlab & Diagnostics Limited

Aspira Pathlab & Diagnostics Limited

ASPIRA.BO
Aspira Pathlab & Diagnostics LimitedIN flagBombay Stock Exchange
125.50
INR
-2.55
- -
1.29BMarket Cap

Total Valuation

Aspira Pathlab & Diagnostics Limited carries a market capitalization of 1.29B, placing it among publicly traded companies globally. Its enterprise value stands at 590.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.29B
Enterprise Value590.70M

Share Statistics

Aspira Pathlab & Diagnostics Limited currently has 10.29M shares outstanding.

Shares Outstanding10.29M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Aspira Pathlab & Diagnostics Limited trades at a trailing price-to-earnings ratio of 8,704.95. The price-to-sales ratio is 2.30, and the price-to-book ratio stands at 5.58.

PE Ratio8,704.95
PS Ratio2.30
PB Ratio5.58
P/TBV Ratio6.45
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Aspira Pathlab & Diagnostics Limited trades at an EV/EBITDA multiple of 94.87 and an EV/FCF ratio of 151.70. The EV/Sales ratio of 2.36 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 94.87 provides insight into valuation relative to core operating earnings.

EV / Sales2.36
EV / EBITDA94.87
EV / EBIT94.87
EV / FCF151.70

Financial Position

Aspira Pathlab & Diagnostics Limited maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.16, indicating elevated leverage, while an interest coverage ratio of -0.18 demonstrates limited ability to service its debt obligations.

Current Ratio1.43
Quick Ratio0.53
Debt / Equity27.16
Debt / EBITDA-46.27
Interest Coverage-0.18

Financial Efficiency

Aspira Pathlab & Diagnostics Limited posts a return on equity of 32.61 and a return on invested capital of -0.49.

Return on Equity (ROE)32.61
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)-0.49
Return on Capital Employed (ROCE)4.23
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover9.69

Stock Price Statistics

Aspira Pathlab & Diagnostics Limited's stock has gained approximately 120.83407% over the past 52 weeks. The 50-day moving average sits at 73.97, while the 200-day moving average is 65.92.

Beta (5Y)N/A
52-Week Price Change120.83407%
50-Day Moving Average73.97
200-Day Moving Average65.92
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Aspira Pathlab & Diagnostics Limited generated 249.82M in revenue and converted that into 66,000.00 in net income, yielding earnings per share of 0.01. EBITDA reached -718,000.00, while operating income came in at -718,000.00.

Revenue249.82M
Gross Profit191.26M
Operating Income-718,000.00
Pretax Income66,459.00
Net Income66,000.00
EBITDA-718,000.00
EBIT-718,000.00
Earnings Per Share (EPS)0.01

Balance Sheet

Aspira Pathlab & Diagnostics Limited holds 17.05M in cash and equivalents against 33.22M in total debt, resulting in a net debt position of 872,000.00. Total book value stands at 102.93M, with working capital of 13.89M providing operational flexibility.

Cash & Cash Equivalents17.05M
Total Debt33.22M
Net Debt872,000.00
Equity (Book Value)102.93M
Book Value Per Share10.01
Working Capital13.89M

Margins

Aspira Pathlab & Diagnostics Limited operates with a gross margin of 76.56, reflecting its pricing power and cost economics. The operating margin of -0.29 and net profit margin of 0.03 provide insight into operational efficiency.

Gross Margin76.56
Operating Margin-0.29
Pretax Margin0.03
Profit Margin0.03
EBITDA Margin-0.29

Scores

Aspira Pathlab & Diagnostics Limited posts an Altman Z-Score of 7.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.23